| Literature DB >> 29650038 |
Emil Hovius1, Arnout de Bruin2, Leo Schouls2, Joppe Hovius3, Niels Dekker4, Hein Sprong2.
Abstract
BACKGROUND: Various tick-borne infections often occur without specific clinical signs and are therefore notoriously hard to diagnose separately in veterinary practice. Longitudinal studies over multiple tick seasons performing clinical, serological and molecular investigations in parallel, may elucidate the relationship between infection and disease. In this regard, six related Rhodesian Ridgeback dogs living as a pack became subject of lifetime studies due to ongoing tick infestations and recurring clinical problems. Blood samples for diagnostic tests were obtained throughout the years 2000 to 2009.Entities:
Keywords: Anaplasma phagocytophilum; Canine granulocytic anaplasmosis; Fever; Persistence; Re-infection; Rhodesian ridgeback dog; Thrombocytopenia
Mesh:
Substances:
Year: 2018 PMID: 29650038 PMCID: PMC5898011 DOI: 10.1186/s13071-018-2806-8
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Fig. 1The pack, six female Rhodesian ridgeback dogs in the large garden adjacent to oak-pinewood forests
Results of serological and molecular diagnostic tests for anaplasmosis on the six Rhodesian ridgeback dogs performed at multiple time points throughout their lives
| Clinic | PCR | Serology | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dog (ID) | Birth- Death | Lethality | VMDC | RIVM 2001 | RIVM 2003 | RIVM 2014 | Total | IFT | Immunoblot | Snap test | Total |
| Whole cell | P44 | P44 | |||||||||
| M12 | 1994–2001 | Splenitis, fever and pain | 1/1 | 1/3, spleen neg | 2/3 | 1/2 | 2/2 | 0/4 | 2/5 | ||
| L11 | 1998–2009 | Malignant tumor in spleen, lung | 1/4 | 2/3 | 2/9 | 3/4, spleen pos | 5/16 | 2/3 | 3/12 | 3/18 | 7/21 |
| L12 | 1998–2005 | Splenitis, fever and pain | 0/1 | 0/1 | 0/1, spleen neg | 0/4 | nd | 0/3 | 3/5 | 3/7 | |
| L13 | 1998–2009 | Haemangiosarcoma | 0/1 | 0/1 | 0/2, spleen neg | 0/5 | nd | 0/2 | 1/6 | 1/6 | |
| L21 | 1999–2005 | Lymphoma | 0/1 | 0/1 | 0/1, spleen neg | 0/3 | nd | 1/2 | 0/6 | 1/7 | |
| N00 | 1995–2009 | Metastasis mammae tumor | 0/1 | 0/1 | 0/1, spleen nd | 0/3 | nd | 1/1 | 2/6 | 3/6 | |
Notes: Different laboratories were involved during the years, employing varying serological and molecular tests. Results are presented separately and overall: (i) The Veterinary Microbiological Diagnostic Center, Veterinary Faculty, Utrecht University, The Netherlands (VMDC) performed serological and molecular tests for ehrlichiae and Babesia as of 2001. Immunofluorescent tests for E. phagocytophilum and E. canis were performed on the 2001 samples; (ii) The National Institute of Public Health and Environment (RIVM) employed an immunoblot with the p44 protein of A. phagocytophilum and amplified the 16S rRNA gene and confirmed the result with RLB (see Methods); (iii) The RIVM followed the same methods in 2003 with another team of technicians; (iv) The molecular detection by the RIVM in 2014 targeted a different set of genes (than in 2 and 3) in blood and spleen tissues (see Methods). The in-house SNAP® 4 Dx test (IDEXX) as serological assay was also employed.
Abbreviations: neg, negative, nd not determined, pos positive
Fig. 2Dog L11 at first presentation in the veterinary clinic, with acute ecchymosis
Fig. 3Dog L11 with the purpura residing within 5 days
Clinical episodes of dog L11 in 2001 and 2002 as determined by symptoms, hematology, serology and pathogen detection by PCR or microscopy. Four clinical episodes were detected in the years 2001, 2002, 2005 and 2008. Symptoms were not always accompanied by fever and bleeding tendency was not always apparent. Other symptoms as lymphadenopathy, muscle pain, lameness, reluctance to move and lethargy were also observed
| Year | 2001 | 2002 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day/Month | 23/04 | 27/04 | 14/05 | 29/06 | 28/08 | 09/02 | 07/03 | 21/06 | 03/09 | 23/09 | 25/09 | 18/10 | |
| Hematology (reference) | |||||||||||||
| Erythrocytes (> 5.5/pl) | 7.05 | 6.21 | 6.78 | 7.84 | 7.56 | 7.11 | 6.75 | 7.15 | 5.72 | 6.33 | 6.46 | ||
| Hemoglobin (> 8.8 mmol/l) | 10.66 | 9.42 | 10.23 | 11.90 | 10.97 | 10.60 | 10.66 | 11.04 |
| 9.05 | 9.61 | ||
| HT (> 42%) | 51 | 46 | 48 | 61 | 56 | 54 | 49 | 52 |
| 43 | 50 | ||
| MCV (65.5–75.5 fl) | 71.70 | 73.60 | 71.10 |
| 73.90 | 75.40 | 73.20 | 72.50 | 67.80 | 68.20 |
| ||
| MCH (0.90–1.55 pmol) | 1.46 | 1.47 | 1.46 | 1.47 | 1.40 | 1.45 | 1.53 | 1.49 | 1.42 | 1.39 | 1.45 | ||
| MCHC (20.9–22.3 mmol/l) | 21.08 | 20.58 | 21.2 |
|
|
| 21.58 | 21.20 | 21.64 | 21.02 |
| ||
| Thrombocytes (150–400/nl) |
|
|
|
|
| 192 | 216 | 180 |
| 187 | 206 | ||
| Leukocytes (5.9–13.8/nl) | 11.4 | 11.6 |
| 8.4 | 8.9 | 7.9 | 7.9 | 8.2 | 7.8 | 6.8 | 8.5 | ||
| Neutrophils (55–75%) | 73 |
| 71 | 55 | 67 | 65 | 66 | 61 |
|
| 73 | ||
| Lymphocytes (13–30%) | 16 | 18 | 16 |
| 22 | 27 | 23 | 33 | 9 |
| 21 | ||
| Monocytes (< 5%) |
| 1 | 4 |
| 5 |
| 2 |
|
| 4 | 5 | ||
| Eosinophils (< 4%) | 2 | 1 |
| 1 |
| 1 |
| 1 | 0 | 2 | 1 | ||
| Basophils (< 1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Staphylococcus (< 4%) | 1 | 1 | 3 | 0 | 2 | 1 | 0 | 0 | 4 | 0 | 0 | ||
| Serology | |||||||||||||
| | Immunoblot | neg2 | neg2 | neg2 | neg3 | neg3 | neg3 | neg3 | neg3 |
|
|
| |
| IFT |
|
| neg1 | ||||||||||
| Snap test | neg | neg | neg | neg | neg | neg |
| neg | |||||
| | WHC-titer | 80 | 40 | ||||||||||
| C6 Snap test | neg | neg | neg | neg | neg | neg | neg | neg | neg | ||||
| Coagulation test | normal | ||||||||||||
| Microscopy (morulae) |
| neg | neg | neg | neg | neg | neg |
| neg | neg | |||
| PCR - DNA |
| neg2 |
| neg2 | neg3 | neg3 | neg3 | neg3,4 |
|
| neg1,3 | ||
| RLB | A. phago variant 1 |
| neg |
| neg | ||||||||
| A. phago variant 2 | neg | neg | neg | neg | |||||||||
| A. phago variant 3 | neg | neg | neg | neg | |||||||||
| A. phago variant 4 | neg |
|
| neg | |||||||||
|
| neg | neg | |||||||||||
| HGE agent | neg | neg |
|
| |||||||||
| Clinics | |||||||||||||
| Body temperature | 38.8 | 38.4 | 38.4 | 38.5 | 38.2 | 38.3 | 38.3 | 38.2 |
| 38.5 | |||
| Bleeding |
|
| no | no | no | no | no | no | no | no | no | no | |
| Other | listless, lymphaden. R popliteus | pseudolac | lame | myositis, lays, pseudolac, lameness | pseudolac | dyspneu | cough | ||||||
| Therapy | doxy | doxy | doxy | doxy | doxy | amox/clv | |||||||
| Ticks on dog | yes | yes | yes | yes | yes | yes | |||||||
Notes: Deviant or positive laboratory results are shown in bold. Serology and Anaplasma DNA detection employed different methods which were performed in different years and laboratories indicated by numbers 1 to 4. Assay method depended on laboratory and year of processing and is indicated as:1VMDC till 2008; 2RIVM in 2001; 3RIVM in 2003; and 4RIVM in 2014. The in-house SNAP® 4Dx test (IDEXX) was employed to determine antibodies against the p44 antigen, which was also detected by immunoblot in the first 2 years as was the IFA (immunofluorescent assay) in the first year. The agent detection by 16S rRNA gene amplification and confirmed by reverse line blot hybridization (RLB) detecting variants of A. phagocytophilum was performed in the first two years. Time of doxycycline therapy and of tick collections from skin are notated
Abbreviations: pos positive, neg negative, pseudolac pseudo-lactation after estrous, OVH spaying by ovariohysterectomym lymphaden lymphadenopathy, ecchm ecchymosis, resolv resolving, A. phago A. phagocytophilum, E. equi Ehrlichia equi, doxy doxycyclin, amox/clv amoxicillin with clavulanic acid
Clinical episodes of dog L11 from 2003 to 2009 as determined by symptoms, hematology, serology and pathogen detection by PCR or microscopy. Symptoms were not always accompanied by fever and bleeding tendency was not always apparent. Other symptoms as lymphadenopathy, muscle pain, lameness, reluctance to move and lethargy were also observed
| Year | 2003 | 2004 | 2005 | 2007 | 2008 | 2009 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day/Month | 18/08 | 09/10 | 19/04 | 29/04 | 09/03 | 29/11 | 27/09 | 17/10 | 22/02 | 11/09 | 12/05 | |
| Hematology (reference) | ||||||||||||
| Erythrocytes (> 5.5/pl) | acanthosis | 7.5 | 7.5 | acanthosis | normal | normal | normal | |||||
| Hemoglobin (> 8.8 mmol/l) | 11.4 | 11,4 | ||||||||||
| HT (> 42%) | 52 |
|
|
| 50 | |||||||
| MCV (65.5–75.5 fl) | 69.5 | |||||||||||
| MCH (0.90–1.55 pmol) | 1.51 | |||||||||||
| MCHC (20.9–22.3 mmol/l) | 21.8 | |||||||||||
| Thrombocytes (150–400/nl) |
|
| 201 | 236 |
| >>> | <<< | < | ||||
| Leukocytes (5.9–13.8/nl) |
| 7 | 6.9 |
| 6 | 10 |
|
| ||||
| Neutrophils (55–75%) |
| 60 | 69 |
|
| 58 |
|
| ||||
| Lymphocytes (13–30%) | 9 | 25 | 23 | 7 | 11 |
|
|
| ||||
| Monocytes (< 5%) | 4 |
| 4 |
| 4 |
|
| |||||
| Eosinophils (< 4%) | 1 | 3 | 4 | 0 | 1 | 2 | 1 | |||||
| Basophils (< 1%) | 0 | 0 | 4 | 0 | ||||||||
| Staphylococcus (< 4%) | 0 | 0 | 0 | |||||||||
| Serology | ||||||||||||
| | Immunoblot | neg | ||||||||||
| IFT | ||||||||||||
| Snap test | neg | neg | neg | neg | neg |
| neg | neg |
| neg | ||
| | WHC-titer | 80 | ||||||||||
| C6 Snap test | neg | neg | neg | neg | neg | neg | neg | neg | neg | neg | ||
| Coagulation/other tests | acanthosis | RF neg | Coombs + | RF neg | hypergamma proteinaemia | |||||||
| Microscopy (morulae) | neg | neg | neg | neg | neg | neg |
| neg | ||||
| PCR - DNA | neg3 | neg1,3 | neg1 | neg1 |
| |||||||
| RLB | A. phago variant 1 | |||||||||||
| A. phago variant 2 | ||||||||||||
| A. phago variant 3 | ||||||||||||
| A. phago variant 4 | ||||||||||||
|
| ||||||||||||
| HGE agent | ||||||||||||
| Clinics | ||||||||||||
| Body temperature | 38.6 | 38.9 |
|
| 38.9 |
| ||||||
| Bleeding | no | no | no | no | no |
| no | no | ||||
| Other | Pseudolac | heart after OVH | non-healing wound | arthrosis in shoulders | dyspneu | lick granuloma | euthanasia | |||||
| Therapy | doxy | doxy | pleiomorphic malignant lung tumour | |||||||||
| Ticks on dog | yes | yes | yes | yes | ||||||||
Notes: Deviant or positive laboratory results are shown in bold. Serology and Anaplasma DNA detection employed different methods which were performed in different years and laboratories indicated by numbers 1 to 4. Assay method depended on laboratory and year of processing and is indicated as:1VMDC till 2008; 2RIVM in 2001; 3RIVM in 2003; and 4RIVM in 2014. The in-house SNAP® 4Dx test (IDEXX) was employed to determine antibodies against the p44 antigen, which was also detected by immunoblot in the first 2 years as was the IFA (immunofluorescent assay) in the first year. The agent detection by 16S rRNA gene amplification and confirmed by reverse line blot hybridization (RLB) detecting variants of A. phagocytophilum was performed in the first two years. Time of doxycycline therapy and of tick collections from skin are notated
Abbreviations: pos positive, neg negative, pseudolac pseudo-lactation after estrous, OVH spaying by ovariohysterectomy, lymphaden lymphadenopathy, ecchm ecchymosis, resolv resolving, A. phago A. phagocytophilum, E. equi Ehrlichia equi, doxy doxycyclin